Xtx Topco LTD Ultragenyx Pharmaceutical Inc. Transaction History

Xtx Topco LTD

$1.81 Billion
Q1 2025

A detailed history of Xtx Topco LTD transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Xtx Topco LTD holds 31,780 shares of RARE stock, worth $1.13 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

31,780

Previous 11,248 182.54%

Holding current value

$1.13 Million

Previous $473,000 143.13%

% of portfolio

0.06%

Previous 0.04%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 07, 2025	BUY	$36.21 - $45.78 $743,463 - $939,954	20,532 Added 182.54%	31,780 $1.15 Million
Q4 2024 Feb 13, 2025	SELL	$42.07 - $57.72 $142,238 - $195,151	-3,381 Reduced 23.11%	11,248 $473,000
Q3 2024 Nov 14, 2024	BUY	$40.21 - $59.36 $286,858 - $423,474	7,134 Added 95.18%	14,629 $812,000
Q2 2024 Aug 12, 2024	SELL	$37.42 - $51.61 $214,266 - $295,518	-5,726 Reduced 43.31%	7,495 $308,000
Q1 2024 May 13, 2024	BUY	$43.02 - $53.69 $250,161 - $312,207	5,815 Added 78.52%	13,221 $617,000
Q4 2023 Feb 13, 2024	SELL	$31.73 - $49.19 $178,100 - $276,103	-5,613 Reduced 43.11%	7,406 $354,000
Q3 2023 Nov 13, 2023	BUY	$34.92 - $46.66 $128,156 - $171,242	3,670 Added 39.26%	13,019 $464,000
Q2 2023 Aug 14, 2023	SELL	$37.35 - $52.15 $67,977 - $94,913	-1,820 Reduced 16.3%	9,349 $431,000
Q1 2023 May 12, 2023	BUY	$36.99 - $48.71 $217,353 - $286,219	5,876 Added 111.01%	11,169 $447,000
Q4 2022 Feb 14, 2023	BUY	$33.72 - $46.33 $178,479 - $245,224	5,293 New	5,293 $245,000

Others Institutions Holding RARE

# of Institutions

336

Shares Held

88.9M

Call Options Held

1.08M

Put Options Held

1.04M

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.5B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account